Drug Trial Radar · NCT01465802
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
Last checked: Nov 20, 2026Latest source record: Jan 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
236
Actual
Start
Dec 26, 2011
Primary completion
May 18, 2015
Study completion May 18, 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent. To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1 mutation, HER-2 mutation or HER-2 amplification).
Conditions
- Non Small Cell Lung Cancer (NSCLC)
Interventions
DacomitinibDrug
Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
DacomitinibDrug
Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
DoxycyclineDrug
Doxycycline or Doxycycline placebo BID for 4 weeks
ProbioticDrug
VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
Alclometasone creamDrug
Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Select Dermatologic Adverse Events of Interest (SDAEI) (All Causality, All Grade) in the First 8 Weeks of Treatment by Treatment Arm for Cohort ITime frame: First 8 Weeks of Treatment
- Percentage of Participants With SDAEI (All Causality, Grade Greater Than or Equal to [≥] 2) in the First 8 Weeks of Treatment by Treatment Arm for Cohort ITime frame: First 8 Weeks of Treatment
- Mean Change From Baseline (Cycle 1 Day 1) Skindex-16 Scale Scores (Total Score, Symptoms Score, Emotion Score, and Functioning Score) by Treatment Arm for Cohort ITime frame: First 8 Weeks of Treatment
- Percentage of Participants With Diarrhea AEs (All Causality, All Grade and Grade ≥2) in the First 8 Weeks of Treatment for Cohort IITime frame: First 8 Weeks of Treatment
- Mean Change From Baseline (Cycle 1 Day 1) Modified Oral Mucositis Daily Questionnaire (OMDQ) Scores (Mouth and Throat Soreness Categories and Scale, and Diarrhea Categories and Scale) for Cohort IITime frame: Cycles 1, 2, 3, 4, 5, and 6, EoT and Follow-up
- Percentage of Participants With SDAEI (All Causality, All Grade) in the First 8 Weeks of Treatment for Cohort IITime frame: First 8 Weeks of Treatment
- Percentage of Participants With SDAEI (All Causality, Grade ≥2) in the First 8 Weeks of Treatment for Cohort IITime frame: First 8 Weeks of Treatment
- Mean Change From Baseline (Cycle 1 Day 1) Skindex-16 Scale Scores (Total Score, Symptoms Score, Emotion Score, and Functioning Score) for Cohort IITime frame: Cycles 1, 2, 3, 4, 5, and 6, EoT and Follow-up
- Mean Area Under the Plasma Concentration Time Curve From 0 to 24 Hours (AUC0-24) and From 0 to 120 Hours (AUC0-120) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort IIITime frame: Cycle 1 Day 10: Pre-dose and 2, 4, 6, 24, 48, 72, 96, and 120 hours post-dose (the 120 hour sample was obtained on Day 15 pre-dose).
- Mean Maximum Observed Plasma Concentrations (Cmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort IIITime frame: Cycle 1 Day 10: Pre-dose and 2, 4, 6, 24, 48, 72, 96, and 120 hours post-dose (the 120 hour sample was obtained on Day 15 pre-dose).
- Median Time of Occurrence of Cmax (Tmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort IIITime frame: Cycle 1 Day 10: Pre-dose and 2, 4, 6, 24, 48, 72, 96, and 120 hours post-dose (the 120 hour sample was obtained on Day 15 pre-dose).
Locations
81 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
St. Jude Heritage Healthcare
Fullerton, California
UCLA Hematology Oncology
Irvine, California
UC San Diego Medical Center - La Jolla
La Jolla, California
UC San Diego Moores Cancer Center - Investigational Drug Services
La Jolla, California
UC San Diego Moores Cancer Center
La Jolla, California
Drug Management Only: UCLA West Medical Pharmacy
Los Angeles, California
Drug Management Only: UCLA West Medical Pharmacy Attn: Steven L. Wong, Pharm.D.
Los Angeles, California
Drug Management Only: UCLA West Medical Pharmacy
Los Angeles, California
Drug Managment Only: UCLA West Medical Pharmacy
Los Angeles, California
Regulatory Management Only TRIO-US Central Administration
Los Angeles, California
Regulatory Management Only: TRIO-US Central Administration
Los Angeles, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCLA Hematology Oncology
Los Angeles, California
Westwood Bowyer Clinic
Los Angeles, California
UCLA/Pasadena HealthCare
Pasadena, California
UC San Diego Medical Center - Hillcrest
San Diego, California
Coastal Integrative Cancer Care
San Luis Obispo, California
SANSUM Clinic
Santa Barbara, California
Cancer Center of Santa Barbara with SANSUM Clinic
Santa Barbara, California
Central Coast Medical Oncology Corporation
Santa Maria, California
UCLA Hematology Oncology
Santa Monica, California
UCLA Santa Monica Medical Center & Orthopaedic Hospital
Santa Monica, California
Cancer Center of Santa Barbara with SANSUM Clinic
Solvang, California
City of Hope South Pasadena Cancer Center
South Pasadena, California
UCLA/Santa Clarita Valley Cancer Center
Valencia, California
UCLA Cancer Center
Westlake Village, California
Kaiser Permanente Colorado - Franklin
Denver, Colorado
St. Mary's Hospital Regional Cancer Center
Grand Junction, Colorado
Kaiser Permanente Colorado - Rock Creek
Lafayette, Colorado
Kaiser Permanente Colorado - Lonetree
Lonetree, Colorado
Michael and Dianne Bienes Comprehensive Cancer Center, Holy Cross Hospital
Fort Lauderdale, Florida
Memorial Cancer Institute
Hollywood, Florida
Cancer Care of North Florida, PA
Lake City, Florida
Memorial West Cancer Institute
Pembroke Pines, Florida
University Cancer & Blood Center, LLC
Athens, Georgia
Summit Cancer Care,PC
Savannah, Georgia
Summit Cancer Care, PC
Savannah, Georgia
Rush University Medical Center, Division of Hematology & Oncology
Chicago, Illinois
Ships Drugs to: Emmanuel Semmes, RPh (or Ami Patel, Pharm D) University of Chicago
Chicago, Illinois
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.